Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

and Hsp-27 positive CTC counts, coupled with decreases in serum PSA and CA-125 levels in patients with prostate and ovarian cancer, markers that strongly suggest single agent anti-cancer activity for OGX-427," said Dr. Sebastien Hotte, Principal Investigator and a medical oncologist at Juravinski Cancer Centre, Hamilton, Ontario.

"We are very satisfied with the safety profile of OGX-427 to date in this trial and the early, strong indicators of anti-tumor and biological activity," said Scott Cormack, president and CEO of OncoGenex Pharmaceuticals.

About OGX-427

OGX-427 is designed to reduce production of Hsp27, a protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy and radiation therapy. Hsp27 production has been shown to inhibit cell death in tumor cells through a variety of mechanisms. OGX-427 is being evaluated in a Phase 1 clinical trial for the treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. Like OGX-011, this product candidate has potential as a treatment in a broad number of cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisen
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...y endpoint has been met for patients with advanced... QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEt... "Company"), a global biopharmaceutical company fo...ounced positive efficacy data from a Phase 2 study...ZS-108 (formerly AN-152), in patients with advance...
(Date:11/24/2009)... 24 Shire plc (LSE: SHP,...eutical company, today,announced that it has submi...laglucerase alfa, the company,s enzyme replacement...1 Gaucher disease. This is the third marketing,app...itted, with previous,submissions in the United Sta...
(Date:11/24/2009)...., Nov. 24 Genomic Healt...y Scott, Genomic Health,s Executive Chairman, will...are Conference in New York City on Tuesday, Decemb...live and subsequently archived webcast of the pres...Genomic Health,s website at http://investor.genom...
(Date:11/24/2009)... Connects Customers with Partners Validated to Pro...k Products , Ottawa, ON (...ng provider of products for biological sample coll...nced its new global partner program. The program o...artner community and is designed to help partners ...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...JAVIK, Iceland, and ALAMEDA, California, April 23,...ration (NASDAQ: CRA ) today announced the signing...ra non-exclusive worldwide licenses to deCODE,s,ge...scular and metabolic,diseases, including heart att...iabetes (T2D). These markers can be incorporated i...
...GCHUN, China and LOS ANGELES, April 23 /PRNewswire...nue Increased 28.6% to $14.1 Million, with Net, ..., - 2008 Revenues Increased 23.5% to $59.1 Mill...ed 340 Basis Points to 20.1%, - 2008 Net Income...of, $0.13, - 2008 Cash Flow from Operation...
...omarker predicts likelihood of recurrence and long...nts; Further strengthens Company,s breast cancer m..., Inc. , (Nasdaq: CLRT ), a premier anatomic pa...r pathologists, oncologists and the pharmaceutical...d an exclusive intellectual property license from ...
Other Biology Technology:deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes 2deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes 3deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes 4deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes 5deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes 6deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes 7China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 2China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 3China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 4China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 5China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 6China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 7China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 8China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 9China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 10China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 11Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation 2Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation 3Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation 4Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation 5
(Date:11/24/2009)...protein that may help gut bacteria bind to the gas...probiotic producers to identify strains that are l...ics need to interact with cells lining the gut to ...rfaces in the gut they are more likely to stick ar... Nathalie Juge from the Institute of Food Research...
(Date:11/24/2009)...ong held secrets of the earth,s history locked in ... very little information on the environments that ... of years. Now, a team of researchers from nine in... tune of $10 million dollars by the National Scien...ngs literally. These scientists will drill throug...
(Date:11/23/2009)...-associated strain of the deadly superbug MRSAan i... antibioticsposes a far greater health threat than...tals, according to a study in the December issue o...eat is easily picked up in fitness centers, school...verall burden of MRSA within hospitals, the report...
Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Custom Spine Announces New Board of Directors and CFO 52778 1Custom Spine Announces New Board of Directors and CFO 52778 2Olympus Managed Health Care Receives Third Party Administrative License in State of Florida 52776 1Northside Medical Center Nurses Reach Tentative Agreement with Forum Health 52774 1
...easing ventilation within aircraft cabins can redu...ggests a review published in this week,s issue of ...Centre, MA, USA) and colleagues reviewed data from...uring commercial air travel. They found that while...r the spread of pathogens carried by passengers or...
...h is more likely to happen - you being in a car wr...red that cars are greater killers win a free trip ... A&M University professor. Your chances of bei... lunch, says John McEachran, a professor of wildli... years. , Worldwide, about one million people a ye...
...ou thought the sleep-deprived months with your new...iller whale. , Reporting in the June 30 edition o...Affairs neuroscientists report a developmental pat... is unique from other mammals, with calves of both...month. , The mother also has minimal sleep during ...
Other Biology News:Aircraft Cabin Ventilation Influences The Transmission Of Diseases In-flight 2New HIV drug candidate developed in Sweden 2Unlike other mammals, newborn dolphins and orcas stay active 24/7 during first months of development 2
... wide range of next-generation features into a sma... for flexible laboratory solutions. It puts every ...lution, dispensing, and integrations into a singl... as it is efficient and economical. The Biomek NX ...
BD Falcon 96-well Flat-bottom ELISA Plates from BD Biosciences - Discovery Labware
Detergent-OUT Micro Kit from CHEMICON
Detergent-OUT (SDS) from CHEMICON
Biology Products: